Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 15.624
Filter
1.
PLoS One ; 19(5): e0302509, 2024.
Article in English | MEDLINE | ID: mdl-38718082

ABSTRACT

BACKGROUND: Soil-transmitted helminthiasis (STH) and schistosomiasis (SCH) are among the most prevalent neglected tropical diseases (NTDs), affecting 1.5 billion globally, with a significant burden in sub-Saharan Africa, particularly Nigeria. These diseases impair health and contribute to socio-economic challenges, especially in children, undermining educational and future economic prospects. The 2030 NTD Roadmap highlights Mass Drug Administration (MDA) as a critical strategy for controlling these NTDs, targeting vulnerable populations like school-age children. Despite some successes, challenges persist, indicating the need for deeper insights into program implementation. This study focuses on the perspectives of health workers implementing MDA in selected local government areas (LGAs) of Ogun State, Nigeria, aiming to identify challenges and enablers that align with the broader NTD 2030 goals. METHODOLOGY/PRINCIPAL FINDINGS: The study used a qualitative research approach involving focus group discussions and in-depth interviews with health workers engaged in neglected tropical disease control programs in Ogun State, Nigeria, between July and September 2022. A semi-structured questionnaire guided the exploration of ideas, and the data were analyzed using the QRS Nvivo 12 software package. The study found that the school-based MDA control program's efficacy largely relies on strong collaborations and partnerships, particularly with educators, community heads, and other stakeholders. These alliances and strategic communication methods, like town announcements and media campaigns, have been pivotal in reaching communities. However, the program does grapple with hurdles such as parental misconceptions, limited funds, insufficient staffing, and misalignment with the Ministry of Education. It is recommended to boost funding, foster early stakeholder involvement, enhance mobilization techniques, and consider introducing a monitoring card system similar to immunization. CONCLUSIONS/SIGNIFICANCE: The MDA Integrated Control Programs for STH and SCH in Ogun State schools demonstrate a holistic approach, integrating knowledge, collaboration, communication, and feedback. Health workers have shown commitment and adeptness in their roles. However, achieving maximum efficacy requires addressing critical barriers, such as parental misconceptions and funding challenges. Adopting the recommended strategies, including proactive communication, increased remuneration, and introducing a tracking system, can significantly enhance the program's reach and impact. The involvement of all stakeholders, from health workers to community leaders and parents, is essential for the program's sustainability and success.


Subject(s)
Health Personnel , Helminthiasis , Mass Drug Administration , Schistosomiasis , Soil , Humans , Nigeria/epidemiology , Schistosomiasis/prevention & control , Schistosomiasis/epidemiology , Schistosomiasis/drug therapy , Helminthiasis/prevention & control , Helminthiasis/epidemiology , Helminthiasis/drug therapy , Soil/parasitology , Male , Female , Schools , Adult , Neglected Diseases/prevention & control , Neglected Diseases/epidemiology , Child , Anthelmintics/therapeutic use , Anthelmintics/administration & dosage , Focus Groups
2.
Nat Commun ; 15(1): 3367, 2024 May 08.
Article in English | MEDLINE | ID: mdl-38719808

ABSTRACT

Soil-transmitted helminths (STHs) are major pathogens infecting over a billion people. There are few classes of anthelmintics and there is an urgent need for new drugs. Many STHs use an unusual form of anaerobic metabolism to survive the hypoxic conditions of the host gut. This requires rhodoquinone (RQ), a quinone electron carrier. RQ is not made or used by vertebrate hosts making it an excellent therapeutic target. Here we screen 480 structural families of natural products to find compounds that kill Caenorhabditis elegans specifically when they require RQ-dependent metabolism. We identify several classes of compounds including a family of species-selective inhibitors of mitochondrial respiratory complex I. These identified complex I inhibitors have a benzimidazole core and we determine key structural requirements for activity by screening 1,280 related compounds. Finally, we show several of these compounds kill adult STHs. We suggest these species-selective complex I inhibitors are potential anthelmintics.


Subject(s)
Anthelmintics , Caenorhabditis elegans , Electron Transport Complex I , Ubiquinone/analogs & derivatives , Animals , Anthelmintics/pharmacology , Anthelmintics/chemistry , Electron Transport Complex I/antagonists & inhibitors , Electron Transport Complex I/metabolism , Caenorhabditis elegans/metabolism , Benzimidazoles/pharmacology , Benzimidazoles/chemistry , Species Specificity , Quinones/chemistry , Quinones/pharmacology , Quinones/metabolism , Biological Products/pharmacology , Biological Products/chemistry
3.
BMC Vet Res ; 20(1): 207, 2024 May 17.
Article in English | MEDLINE | ID: mdl-38760783

ABSTRACT

BACKGROUND: Although ultrasonography (US) has been widely used in the diagnosis of human diseases to monitor the progress of cystic echinococcosis (CE) control, the screening method for hepatic CE in sheep flocks requires adjustment. In this study, we used a US scanner to screen sheep flocks and evaluated the efficacy of dosing dogs once a year with praziquantel for 7 years from 2014 to 2021. METHODS: All sheep in the three flocks were screened using an ultrasound scanner in 2014 and compared with the prevalence of infection in 2021 in Bayinbuluke, Xinjiang, China. Sheep age was determined using incisor teeth. Cyst activity and calcification were determined using US images. The dogs were dewormed with praziquantel once a year to control echinococcosis in the community. RESULTS: Three flocks had 968 sheep in 2014, with 13.22%, 22.62%, 18.7%, 27.27%, 11.88%, and 6.3% of sheep aged 1, 2, 3, 4, 5, and ≥ 6 years old, respectively. US scanning revealed that the overall CE prevalence was 38.43% (372/968), with active cysts and calcified cysts present in 9.40% (91/968) and 29.02% (281/968) of the sheep, respectively. For the young sheep aged 1 and 2 years, the prevalence of active and calcified cysts was: 1.56% and 0.91%, and 10.94% and 18.72%, respectively. Approximately 15.15% and 16.52% of the 4- and 5-year-old sheep, respectively, harbored active cysts. There was no significant difference in the infection rates of sheep between 2014 and 2021 (P > 0.05). CONCLUSIONS: US is a practical tool for the field screening of CE in sheep flocks. One-third of the sheep population in the flocks was 1-2 years old, and these sheep played a very limited role in CE transmission, as most of the cysts were calcified. Old sheep, especially culled aged sheep, play a key role in the transmission of CE. Dosing dogs once a year did not affect echinococcosis control.


Subject(s)
Echinococcosis, Hepatic , Sheep Diseases , Ultrasonography , Animals , Sheep Diseases/epidemiology , Sheep Diseases/parasitology , Sheep Diseases/diagnostic imaging , Sheep , China/epidemiology , Ultrasonography/veterinary , Echinococcosis, Hepatic/veterinary , Echinococcosis, Hepatic/epidemiology , Echinococcosis, Hepatic/diagnostic imaging , Prevalence , Dogs , Praziquantel/therapeutic use , Anthelmintics/therapeutic use , Female
4.
Vet Parasitol Reg Stud Reports ; 51: 101028, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38772650

ABSTRACT

In Australian pastoral dairy systems, a variety of 'routine' anthelmintic programs are used in lactating cows varying from nil anthelmintic use to bi-annual application. Anthelmintic resistance has been repeatedly diagnosed on dairy farms and studies have indicated variable milk production benefits from anthelmintics internationally. We aimed to identify the predominant gastrointestinal parasites in recently calved dairy cows in south-west Victoria and examined the relationship between individual faecal egg counts (FEC) and other cow and management factors such as body condition score, age, and historical anthelmintic use. This study included 18 pasture-based dairy farms in south-west Victoria. FECs were measured in recently calved primiparous and multiparous cows. Individual FEC tests with a minimum detectable FEC of 2.5 eggs per gram of faeces (epg) and group larval cultures were completed. Farm management data and cow information was recorded for data analysis with the Jamovi statistical package. Overall, 35% of all cows had FEC ≥ 2.5 epg (26% of multiparous and 45% of primiparous). Ostertagi ostertagi was the predominant gastrointestinal nematode in all cohorts. Cooperia pectinata or C. punctata were also present in mixed infestations alongside C. oncophora. Multiparous cows in low body condition score post calving (<4) were more likely to have a FEC of >5 epg. Faecal egg counts at a minimum detectable FEC of 2.5 epg are effective indicators of parasitism in recently calved primiparous and poorly conditioned multiparous dairy cows. Increasing the test sensitivity (minimum detectable count) of FECs from 10 epg to 2.5 epg resulted in increasing the overall positive FEC rate from 15% to 35%. Further investigation of sensitive FECs and their relevance to production along with the timing and value of anthelmintic use in dairy cattle is warranted.


Subject(s)
Anthelmintics , Cattle Diseases , Dairying , Feces , Parasite Egg Count , Animals , Cattle , Feces/parasitology , Female , Parasite Egg Count/veterinary , Cattle Diseases/parasitology , Cattle Diseases/epidemiology , Cattle Diseases/drug therapy , Victoria/epidemiology , Anthelmintics/therapeutic use , Anthelmintics/pharmacology , Australia
5.
J Helminthol ; 98: e40, 2024 May 13.
Article in English | MEDLINE | ID: mdl-38738533

ABSTRACT

In the past decade, interest has significantly increased regarding the medicinal and nutritional benefits of pomegranate (Punica granatum) peel. This study examined the effects of using pomegranate peel extract (PGE) alone and in combination with albendazole (ABZ) on ultrastructural and immunological changes in cystic echinococcosis in laboratory-infected mice. Results revealed that the smallest hydatid cyst size and weight (0.48 ± 0.47mm, 0.17 ± 0.18 gm) with the highest drug efficacy (56.2%) was detected in the PGE + ABZ group, which also exhibited marked histopathological improvement. Ultrastructural changes recorded by transmission electron microscopy including fragmentation of the nucleus, glycogen depletion, and multiple lysosomes in vacuolated cytoplasm were more often observed in PGE + ABZ group. IFN-γ levels were significantly increased in the group treated with ABZ, with a notable reduction following PGE treatment, whether administered alone or in combination with ABZ. Thus, PGE enhanced the therapeutic efficiency of ABZ, with improvement in histopathological and ultrastructural changes.


Subject(s)
Albendazole , Echinococcosis , Plant Extracts , Pomegranate , Animals , Plant Extracts/pharmacology , Plant Extracts/administration & dosage , Pomegranate/chemistry , Mice , Echinococcosis/drug therapy , Echinococcosis/parasitology , Albendazole/pharmacology , Albendazole/administration & dosage , Anthelmintics/pharmacology , Anthelmintics/administration & dosage , Disease Models, Animal , Microscopy, Electron, Transmission , Interferon-gamma/blood , Female , Male
6.
Parasit Vectors ; 17(1): 211, 2024 May 10.
Article in English | MEDLINE | ID: mdl-38730429

ABSTRACT

BACKGROUND: The health and productivity of dairy goats continue to be impacted by gastrointestinal nematodes (GIN) and lungworms (LW). Eprinomectin (EPN) is frequently selected for treatment because it is generally effective and does not require a milk withdrawal period. However, some factors, such as lactation, can have an impact on EPN pharmacokinetics and potentially its efficacy. To evaluate whether this can alter the efficacy of Eprecis® 2%, an eprinomectin injectable solution, a study was performed in lactating goats using the dose currently registered in cattle, sheep and goats (0.2 mg/kg). METHODS: This study was a blinded, randomized, controlled trial performed according to the VICH guidelines. Eighteen (18) worm-free lactating goats were included and experimentally challenged on day 28 with a mixed culture of infective gastrointestinal and lung nematode larvae (Haemonchus contortus, Trichostrongylus colubriformis, Teladorsagia circumcincta, Dictyocaulus filaria). At D-1, fecal samples were collected to confirm patent infection in all animals. On D0, the goats were randomly allocated into two groups of nine goats; group 1 was treated with Eprecis® 2% at 0.2 mg/kg BW by subcutaneous injection, while group 2 remained untreated. Fecal samples for egg counts were collected from all animals on days 3, 5, 7, 9, 11 and 14. On D14, all goats were killed, and the abomasum, small intestine and lungs were removed, processed and subsampled to record the number and species of worms. RESULTS: The treatment was well tolerated. After treatment, the arithmetic mean FEC decreased in the treated group and remained < 5 EPG until the end of the study, while the arithmetic mean FEC in the control group remained > 849.0 EPG. At D14, goats in the treated group had very limited or zero total worm counts, whereas all animals from the control group had a high worm burden. The measured efficacy was 100.0% against H. contortus and T. colubriformis, 99.9% against T. circumcincta and 98.0% against D. filaria. CONCLUSIONS: Eprinomectin (Eprecis®, 20 mg/ml), administered at the label dose (0.2 mg/kg), is highly effective against gastrointestinal nematodes and lungworms in lactating goats.


Subject(s)
Feces , Goat Diseases , Goats , Ivermectin , Lactation , Nematode Infections , Animals , Ivermectin/analogs & derivatives , Ivermectin/administration & dosage , Ivermectin/pharmacokinetics , Ivermectin/therapeutic use , Goat Diseases/drug therapy , Goat Diseases/parasitology , Female , Nematode Infections/veterinary , Nematode Infections/drug therapy , Nematode Infections/parasitology , Feces/parasitology , Lactation/drug effects , Parasite Egg Count/veterinary , Injections, Subcutaneous/veterinary , Anthelmintics/administration & dosage , Anthelmintics/therapeutic use , Anthelmintics/pharmacokinetics , Nematoda/drug effects , Gastrointestinal Diseases/veterinary , Gastrointestinal Diseases/parasitology , Gastrointestinal Diseases/drug therapy , Lung/parasitology
7.
Parasitol Res ; 123(5): 215, 2024 May 21.
Article in English | MEDLINE | ID: mdl-38771511

ABSTRACT

Schistosomiasis is a neglected tropical disease associated with considerable morbidity. Praziquantel (PZQ) is effective against adult schistosomes, yet, it has little effect on juvenile stages, and PZQ resistance is emerging. Adopting the drug repurposing strategy as well as assuming enhancing the efficacy and lessening the doses and side effects, the present study aimed to investigate the in vivo therapeutic efficacy of the widely used antiarrhythmic, amiodarone, and diuretic, spironolactone, and combinations of them compared to PZQ. Mice were infected by Schistosoma mansoni "S. mansoni" cercariae (Egyptian strain), then they were divided into two major groups: Early- [3 weeks post-infection (wpi)] and late- [6 wpi] treated. Each group was subdivided into seven subgroups: positive control, PZQ, amiodarone, spironolactone, PZQ combined with amiodarone, PZQ combined with spironolactone, and amiodarone combined with spironolactone-treated groups. Among the early-treated groups, spironolactone had the best therapeutic impact indicated by a 69.4% reduction of total worm burden (TWB), 38.6% and 48.4% reduction of liver and intestine egg load, and a significant reduction of liver granuloma number by 49%. Whereas, among the late-treated groups, amiodarone combined with PZQ was superior to PZQ alone evidenced by 96.1% reduction of TWB with the total disappearance of female and copula in the liver and intestine, 53.1% and 84.9% reduction of liver and intestine egg load, and a significant reduction of liver granuloma number by 67.6%. Comparatively, spironolactone was superior to PZQ and amiodarone in the early treatment phase targeting immature stages, while amiodarone had a more potent effect when combined with PZQ in the late treatment phase targeting mature schistosomes.


Subject(s)
Amiodarone , Disease Models, Animal , Praziquantel , Schistosoma mansoni , Schistosomiasis mansoni , Animals , Schistosomiasis mansoni/drug therapy , Schistosomiasis mansoni/parasitology , Mice , Schistosoma mansoni/drug effects , Praziquantel/therapeutic use , Praziquantel/pharmacology , Amiodarone/therapeutic use , Amiodarone/pharmacology , Female , Spironolactone/therapeutic use , Spironolactone/pharmacology , Schistosomicides/therapeutic use , Schistosomicides/pharmacology , Male , Anthelmintics/therapeutic use , Anthelmintics/pharmacology , Treatment Outcome , Drug Therapy, Combination , Liver/parasitology
8.
Fish Shellfish Immunol ; 149: 109613, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38710341

ABSTRACT

Aporocotylids (Trematoda: Digenea), also known as fish blood flukes infect the circulatory system of fish leading to serious health problems and mortality. Aporocotylids are a particular concern for farmed fish as infection intensity can increase within the farming environment and lead to mortalities. In the context of managing these infections, one of the most crucial aspects to consider is the host response of the infected fish against these blood flukes. Understanding the response is essential to improving current treatment strategies that are largely based on the use of anthelmintic praziquantel to manage infections in aquaculture. This review focuses on the current knowledge of farmed fish host responses against the different life stages of aporocotylids. New treatment strategies that are able to provide protection against reinfections should be a long-term goal and is not possible without understanding the fish response to infection and the interactions between host and parasite.


Subject(s)
Aquaculture , Fish Diseases , Fishes , Trematoda , Trematode Infections , Animals , Trematode Infections/veterinary , Trematode Infections/immunology , Trematode Infections/parasitology , Trematode Infections/drug therapy , Fish Diseases/immunology , Fish Diseases/parasitology , Trematoda/physiology , Fishes/immunology , Fishes/parasitology , Host-Parasite Interactions , Anthelmintics/therapeutic use , Anthelmintics/pharmacology
9.
BMC Complement Med Ther ; 24(1): 183, 2024 May 04.
Article in English | MEDLINE | ID: mdl-38704537

ABSTRACT

BACKGROUND: Highlighting affordable alternative crops that are rich in bioactive phytoconstituents is essential for advancing nutrition and ensuring food security. Amaranthus blitum L. (AB) stands out as one such crop with a traditional history of being used to treat intestinal disorders, roundworm infections, and hemorrhage. This study aimed to evaluate the anthelmintic and hematologic activities across various extracts of AB and investigate the phytoconstituents responsible for these activities. METHODS: In vitro anthelmintic activity against Trichinella spiralis was evaluated in terms of larval viability reduction. The anti-platelet activities were assessed based on the inhibitory effect against induced platelet aggregation. Further, effects on the extrinsic pathway, the intrinsic pathway, and the ultimate common stage of blood coagulation, were monitored through measuring blood coagulation parameters: prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT), respectively. The structures of isolated compounds were elucidated by spectroscopic analysis. RESULTS: Interestingly, a previously undescribed compound (19), N-(cis-p-coumaroyl)-ʟ-tryptophan, was isolated and identified along with 21 known compounds. Significant in vitro larvicidal activities were demonstrated by the investigated AB extracts at 1 mg/mL. Among tested compounds, compound 18 (rutin) displayed the highest larvicidal activity. Moreover, compounds 19 and 20 (N-(trans-p-coumaroyl)-ʟ-tryptophan) induced complete larval death within 48 h. The crude extract exhibited the minimal platelet aggregation of 43.42 ± 11.69%, compared with 76.22 ± 14.34% in the control plasma. Additionally, the crude extract and two compounds 19 and 20 significantly inhibited the extrinsic coagulation pathway. CONCLUSIONS: These findings extend awareness about the nutritional value of AB as a food, with thrombosis-preventing capabilities and introducing a promising source for new anthelmintic and anticoagulant agents.


Subject(s)
Amaranthus , Anthelmintics , Anticoagulants , Phytochemicals , Plant Extracts , Platelet Aggregation Inhibitors , Animals , Anthelmintics/pharmacology , Plant Extracts/pharmacology , Plant Extracts/chemistry , Phytochemicals/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Anticoagulants/pharmacology , Larva/drug effects
10.
Parasitol Res ; 123(5): 207, 2024 May 07.
Article in English | MEDLINE | ID: mdl-38713234

ABSTRACT

Biomarkers are specific molecular, histological, or physiological characteristics of normal or pathogenic biological processes and are promising in the diagnosis of gastrointestinal nematodes (GINs). Although some biomarkers have been validated for infection by Ostertagia sp. in cattle raised in temperate regions, there is a lack of information for tropical regions. The aim of this project was to assess potential biomarkers and validate the most promising. In the first study, 36 bovines (Nelore breed) naturally infected by GINs were distributed into two groups: infected (not treated with anthelmintic) and treated (treated with fenbendazole on days 0, 7, 14, 21, 28, 42, and 56). The variables of interest were live weight, fecal egg count, hemogram, serum biochemical markers, phosphorus, gastrin, and pepsinogen. In the second step, pepsinogen was assessed in cattle of the Nelore breed distributed among three groups: infected (not treated with anthelmintic), MOX (treated with moxidectin), and IVM + BZD (treated with ivermectin + albendazole). In the first study, no difference between groups was found for weight, albumin, hematocrit (corpuscular volume [CV]), erythrocytes, or hemoglobin. Negative correlations were found between pepsinogen and both CV and albumin, and albumin was negatively correlated with the percentage of Haemonchus sp. in the fecal culture. Among the biomarkers, only pepsinogen differentiated treated and infected (beginning with the 28th day of the study). In the second study, a reduction in pepsinogen was found after anthelmintic treatment. Therefore, pepsinogen is a promising biomarker of worms in cattle naturally infected by the genera Haemonchus and Cooperia in tropical areas.


Subject(s)
Biomarkers , Cattle Diseases , Feces , Nematode Infections , Tropical Climate , Animals , Cattle , Cattle Diseases/parasitology , Cattle Diseases/drug therapy , Biomarkers/blood , Nematode Infections/veterinary , Nematode Infections/parasitology , Nematode Infections/drug therapy , Feces/parasitology , Parasite Egg Count , Anthelmintics/therapeutic use , Nematoda/isolation & purification , Nematoda/classification , Nematoda/drug effects , Gastrointestinal Diseases/parasitology , Gastrointestinal Diseases/veterinary , Intestinal Diseases, Parasitic/veterinary , Intestinal Diseases, Parasitic/parasitology , Fenbendazole/therapeutic use
12.
Parasit Vectors ; 17(1): 225, 2024 May 16.
Article in English | MEDLINE | ID: mdl-38755679

ABSTRACT

BACKGROUND: The giant roundworm Ascaris is an intestinal nematode, causing ascariasis by infecting humans and pigs worldwide. Recent estimates suggest that Ascaris infects over half a billion people, with chronic infections leading to reduced growth and cognitive ability. Ascariasis affects innumerable pigs worldwide and is known to reduce production yields via decreased growth and condemnation of livers. The predominant anthelminthic drugs used to treat ascariasis are the benzimidazoles. Benzimidazoles interact with ß-tubulins and block their function, and several benzimidazole resistance-associated mutations have been described in the ß-tubulins of ruminant nematodes. Recent research on ascarids has shown that these canonical benzimidazole resistance-associated mutations are likely not present in the ß-tubulins of Ascaris, Ascaridia or Parascaris, even in phenotypically resistant populations. METHODS: To further determine the putative absence of key ß-tubulin polymorphisms, we screened two ß-tubulin isotypes of Ascaris, highly expressed in adult worms. Using adult and egg samples of Ascaris obtained from pigs and humans worldwide, we performed deep amplicon sequencing to look for canonical resistance-associated mutations in Ascaris ß-tubulins. Subsequently, we examined these data in closer detail to study the population dynamics of Ascaris and genetic diversity within the two isotypes and tested whether genotypes appeared to partition across human and pig hosts. RESULTS: In the 187 isolates, 69 genotypes were found, made up of eight haplotypes of ß-tubulin isotype A and 20 haplotypes of isotype B. Single nucleotide polymorphisms were seen at 14 and 37 positions for ß-tubulin isotype A and isotype B, respectively. No evidence of any canonical benzimidazole resistance-associated mutations was found in either human- or pig-derived Ascaris isolates. There was, however, a difference in the genetic diversity of each isotype and distribution of ß-tubulin genotypes between human- and pig-derived Ascaris. Statistical tests of population differentiation show significant differences (p < 0.001) between pig- and human-derived worms; however, more diversity was seen between worms from different populations than worms from different hosts. CONCLUSIONS: Our work suggests an absence of canonical ß-tubulin mutations within Ascaris, but alternative modes of anthelminthic resistance may emerge necessitating continued genetic scrutiny alongside monitoring of drug efficacy.


Subject(s)
Anthelmintics , Ascariasis , Ascaris , Benzimidazoles , Drug Resistance , Mutation , Tubulin , Tubulin/genetics , Animals , Benzimidazoles/pharmacology , Drug Resistance/genetics , Ascariasis/parasitology , Ascariasis/veterinary , Ascariasis/drug therapy , Anthelmintics/pharmacology , Swine , Ascaris/genetics , Ascaris/drug effects , Humans , Swine Diseases/parasitology , Swine Diseases/drug therapy
13.
PLoS One ; 19(5): e0300384, 2024.
Article in English | MEDLINE | ID: mdl-38758736

ABSTRACT

BACKGROUND: Hundreds of millions of doses of Praziquantel (PZQ) have been administered to persons with and without schistosomiasis living in schistosomiasis endemic settings, through the mass drug administration (MDA) strategy which started in the early 2000s. A recent publication suggested high risk of PZQ-related visual disorders, raising public health concerns. We aim to systematically synthesize evidence on the magnitude of PZQ-related visual disorders. METHODS: We will search PubMed, Google Scholar, CINAHL, SCOPUS, CENTRAL and LILACS from 1977 (when the first human clinical trials on PZQ started) to 31st May 2024, with no language restrictions. The key search terms will include "Praziquantel", "PZQ", "visual disorder", "adverse events", "side effects", "blurry vision" and "visual impairment" together with alternative terms and synonyms. All the countries endemic for schistosomiasis will be included as search terms. We will also search HINARI, Africa Journals Online, Thesis Databases and Preprint Repositories. Where necessary, we will contact expert researchers working in the field of schistosomiasis, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), pharmaceutical industries, country-specific Food and Drug Authorities (FDAs) and the European Medicines Agency databases. We will search Conference Proceedings and reference lists of relevant studies for additional studies. At least two authors will independently select studies, extract data and assess risk of bias in the included studies. Any disagreements or discrepancies will be resolved through discussion between the reviewers. Heterogeneity will be explored graphically, and statistically using the I2-statistic. We will conduct random-effects meta-analysis when heterogeneity is appreciable, and express dichotomous outcomes (visual adverse events including excessive lacrimation, blurry vision and visual impairments) as risk ratio (RR) or Odds Ratio (OR) with their 95% confidence interval (CI). We will perform subgroup analysis to assess the impact of heterogeneity, and sensitivity analyses to test the robustness of the effect estimates. The overall level of evidence will be assessed using GRADE. EXPECTED OUTCOMES: The present review expects to identify and categorize visual disorders occurring after administration of PZQ, alone or in combination with other drugs. By synthesizing the data from multiple studies, the review aims to present a quantitative assessment of the risk or odds of experiencing a visual disorder in different populations after ingesting PZQ. The review will also generate insights into whether PZQ in combination with other drugs are associated with increased odds of visual disorders and whether the occurrence of visual disorders correlates with dosage or treatment duration. Policymakers, public health experts and stakeholders could rely on the review findings to deliver context-sensitive preventive chemotherapy programs by adjusting drug combinations or dosing schedules to reduce risk of visual adverse effects in populations treated with PZQ. The review aims to identify gaps in the current evidence regarding visual disorders following PZQ administration in schistosomiasis endemic settings which can serve as the basis for future research on important but unanswered questions. DISSEMINATION AND PROTOCOL REGISTRATION: The findings of this study will be disseminated through stakeholder forums, conferences, and peer-review publications. The review protocol has been registered in the International Prospective Register for Systematic Reviews (PROSPERO)- CRD42023417963.


Subject(s)
Mass Drug Administration , Praziquantel , Schistosomiasis , Systematic Reviews as Topic , Vision Disorders , Humans , Schistosomiasis/epidemiology , Schistosomiasis/prevention & control , Schistosomiasis/drug therapy , Praziquantel/therapeutic use , Praziquantel/adverse effects , Praziquantel/administration & dosage , Vision Disorders/epidemiology , Vision Disorders/chemically induced , Meta-Analysis as Topic , Endemic Diseases/prevention & control , Anthelmintics/therapeutic use , Anthelmintics/administration & dosage , Anthelmintics/adverse effects
14.
PLoS One ; 19(5): e0301464, 2024.
Article in English | MEDLINE | ID: mdl-38696510

ABSTRACT

Preventive chemotherapy by mass drug administration is globally recommended as the primary method of reaching the elimination of schistosomiasis, especially in the high risk-paediatric population. This systematic review provides a summary of the effects of paediatric schistosomiasis control programs on eliminating schistosomiasis in sub-Saharan Africa. A systematic search was conducted in PubMed, EBSCOhost, and other databases to obtain studies regarding the effects of paediatric schistosomiasis control programmes in sub-Saharan Africa. 3455 studies were screened for eligibility, included articles reported on both paediatrics control programmes and schistosomiasis, and articles were excluded when they did not report on schistosomiasis control programmes in paediatrics exclusively. 40 selected studies were critically appraised using the JBI critical appraisal tools for relevance and 30 studies were included in the study. An in-depth quantitative descriptive analysis was conducted, and a comprehensive narrative summary explained the results within the scope of the review questions. The results show that despite preventive chemotherapy lowering schistosomiasis prevalence, chances of re-infection are high in endemic areas. Preventive chemotherapy without complementary interventions including safe water provision and proper sanitation, snail control and health education on the aetiology of schistosomiasis, transmission pattern and control practices might not eliminate schistosomiasis.


Subject(s)
Schistosomiasis , Humans , Africa South of the Sahara/epidemiology , Schistosomiasis/prevention & control , Schistosomiasis/epidemiology , Schistosomiasis/transmission , Child , Animals , Anthelmintics/therapeutic use , Prevalence , Mass Drug Administration
15.
BMC Vet Res ; 20(1): 214, 2024 May 20.
Article in English | MEDLINE | ID: mdl-38769544

ABSTRACT

As an orally effective benzimidazole anthelmintic agent, fenbendazole was not only widely used in agriculture and animal husbandry to prevent and treat parasites, but also shows anti-cancer effects against several types of cancer, exhibits anti-cancer effects in paclitaxel and doxorubicin-resistant cancer cells. However, fenbendazole's poor in water solubility (0.3 µg/mL), limits its clinical applications. Even great efforts were made toward increasing its water solubility, the results were not significant to reach anti-cancer drug delivery requirement (5-10 mg/mL). Through single factor and orthogonal strategy, many complex conditions were designed and used to prepare the complexes, the inclusion complex with methyl-ß-cyclodextrin with 29.2 % of inclusion rate and 89.5% of inclusion yield can increase drug's water solubility to 20.21 mg/mL, which is the best result so far. Its structure was confirmed by differential scanning calorimetry, scanning electron microscopic image, 1D and 2D NMR spectra in D2O. In its in vitro pharmacokinetic study, fenbendazole was 75% released in 15 min., in its in vivo pharmacokinetic study, the bio-availabilities of fenbendazole, its major metabolic anthelmintic agent oxfendazole and its minor metabolic anthelmintic agent oxfendazole were increased to 138%, 149% and 169% respectively, which would allow for fewer drug doses to achieve the same therapeutic effect and suggest that the complex can be used as a potential anticancer agent.


Subject(s)
Fenbendazole , Solubility , beta-Cyclodextrins , Fenbendazole/pharmacokinetics , Fenbendazole/therapeutic use , Fenbendazole/chemistry , Animals , beta-Cyclodextrins/chemistry , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/chemistry , Antineoplastic Agents/administration & dosage , Male , Anthelmintics/pharmacokinetics , Anthelmintics/chemistry , Anthelmintics/administration & dosage
16.
Parasit Vectors ; 17(1): 173, 2024 Apr 03.
Article in English | MEDLINE | ID: mdl-38570858

ABSTRACT

BACKGROUND: Control of the zoonotic food-borne parasite Fasciola hepatica remains a major challenge in humans and livestock. It is estimated that annual economic losses due to fasciolosis can reach US$3.2 billion in agriculture and livestock. Moreover, the wide distribution of drug-resistant parasite populations and the absence of a vaccine threaten sustainable control, reinforcing the need for novel flukicides. METHODS: The present work analyses the flukicidal activity of a total of 70 benzimidazole derivatives on different stages of F. hepatica. With the aim to select the most potent ones, and screenings were first performed on eggs at decreasing concentrations ranging from 50 to 5 µM and then on adult worms at 10 µM. Only the most effective compounds were also evaluated using a resistant isolate of the parasite. RESULTS: After the first screenings at 50 and 10 µM, four hit compounds (BZD31, BZD46, BZD56, and BZD59) were selected and progressed to the next assays. At 5 µM, all hit compounds showed ovicidal activities higher than 71% on the susceptible isolate, but only BZD31 remained considerably active (53%) when they were tested on an albendazol-resistant isolate, even with values superior to the reference drug, albendazole sulfoxide. On the other hand, BZD59 displayed a high motility inhibition when tested on adult worms from an albendazole-resistant isolate after 72 h of incubation. CONCLUSIONS: BZD31 and BZD59 compounds could be promising candidates for the development of fasciolicidal compounds or as starting point for the new synthesis of structure-related compounds.


Subject(s)
Anthelmintics , Fasciola hepatica , Fascioliasis , Animals , Humans , Anthelmintics/pharmacology , Anthelmintics/therapeutic use , Benzimidazoles/pharmacology , Benzimidazoles/therapeutic use , Fascioliasis/parasitology , Antinematodal Agents/therapeutic use
17.
J Ethnopharmacol ; 328: 118132, 2024 Jun 28.
Article in English | MEDLINE | ID: mdl-38565411

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Infections caused by parasitic worms or helminth continue to pose a great burden on human and animal health, particularly in underdeveloped tropical and subtropical countries where they are endemic. Current anthelmintic drugs present serious limitations and the emergence of drug resistance has made it increasingly challenging to combat such infections (helminthiases). In Bangladesh, medicinal plants are often used by indigenous communities for the treatment of helminthiases. Knowledge on such plants along with screening for their anthelmintic activity has the potential to lead to the discovery of phytochemicals that could serve as novel molecular scaffolds for the development of new anthelminthic drugs. AIM OF THE STUDY: The purpose of this study was i) to conduct an ethnobotanical survey to gather data on Bangladeshi medicinal plants used in the treatment of helminthiases, ii) to test plants with the highest use values for their in vitro anthelmintic activity, and iii) to carry out in silico screening on phytochemicals present in the most active plant extract to investigate their ability to disrupt ß-tubulin function in helminths. METHODS: The ethnobotanical survey was conducted across three sub-districts of Bangladesh, namely Mathbaria, Phultala and Khan Jahan Ali. The in vitro screening for anthelmintic activity was performed in a motility test using adult Haemonchus contortus worms. Virtual screening using PyRx was performed on the phytochemicals reported from the most active plant, exploring their interactions with the colchicine binding site of the ß-tubulin protein target (PDB ID: 1SA0). RESULTS: The survey respondents reported a total of 32 plants for treating helminthiases. Based on their use values, the most popular choices were Ananas comosus (L.) Merr., Azadirachta indica A.Juss., Carica papaya L., Citrus maxima (Burm.) Merr., Curcuma longa L., Momordica charantia L., Nigella sativa L. and Syzygium cumini (L.) Skeels. In vitro anthelmintic testing revealed that A. indica leaves and bark had the highest activity with LC50 values of 16 mg/mL in both cases. Other plant extracts also exhibited good anthelmintic activity with LC50 values ranging from 16 to 52 mg/mL, while the value for albendazole (positive control) was 8.39 mg/mL. The limonoids nimbolide and 28-deoxonimbolide showed a binding affinity of -8.9 kcal/mol, and satisfied all drug-likeness parameters. The control ligand N-deacetyl-N-(2-mercaptoacetyl)colchicine had a binding affinity of -6.9 kcal/mol. CONCLUSION: Further in silico and in vitro studies are warranted on the identified limonoids to confirm the potential of these derivatives as novel drug templates for helminthiases. The current study supports the need for an ethnobotanical survey-based approach to discover novel drug templates for helminthiases.


Subject(s)
Anthelmintics , Haemonchus , Helminthiasis , Limonins , Plants, Medicinal , Adult , Animals , Humans , Plants, Medicinal/chemistry , Tubulin , Anthelmintics/pharmacology , Plant Extracts/pharmacology , Plant Extracts/chemistry , Phytochemicals/pharmacology , Colchicine
18.
ACS Infect Dis ; 10(5): 1664-1678, 2024 May 10.
Article in English | MEDLINE | ID: mdl-38686397

ABSTRACT

In this study, we have identified and optimized two lead structures from an in-house screening, with promising results against the parasitic flatworm Schistosoma mansoni and its target protease S. mansoni cathepsin B1 (SmCB1). Our correlation analysis highlighted the significance of physicochemical properties for the compounds' in vitro activities, resulting in a dual approach to optimize the lead structures, regarding both phenotypic effects in S. mansoni newly transformed schistosomula (NTS), adult worms, and SmCB1 inhibition. The optimized compounds from both approaches ("phenotypic" vs "SmCB1" approach) demonstrated improved efficacy against S. mansoni NTS and adult worms, with 2h from the "SmCB1" approach emerging as the most potent compound. 2h displayed nanomolar inhibition of SmCB1 (Ki = 0.050 µM) while maintaining selectivity toward human off-target cathepsins. Additionally, the greatly improved efficacy of compound 2h toward S. mansoni adults (86% dead worms at 10 µM, 68% at 1 µM, 35% at 0.1 µM) demonstrates its potential as a new therapeutic agent for schistosomiasis, underlined by its improved permeability.


Subject(s)
Cathepsin B , Schistosoma mansoni , Schistosoma mansoni/drug effects , Schistosoma mansoni/enzymology , Schistosoma mansoni/genetics , Animals , Cathepsin B/antagonists & inhibitors , Cathepsin B/metabolism , Schistosomiasis mansoni/drug therapy , Drug Design , Humans , Phenotype , Structure-Activity Relationship , Anthelmintics/pharmacology , Anthelmintics/chemistry , Helminth Proteins/antagonists & inhibitors
19.
Parasitology ; 151(5): 523-528, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38571299

ABSTRACT

Dipylidium caninum is a common tapeworm of dogs. Two cases of praziquantel resistance have been described in D. caninum in the United States. No further reports have been published to the authors' knowledge. Here, the case of a dog imported to Switzerland from Spain with a history of chronic excretion of tapeworm proglottids and unresponsiveness to praziquantel treatments is reported. Clinical signs were mild (restlessness, tenesmus, anal pruritus, squashy feces) and flea infestation could be ruled out. Infection with D. caninum was confirmed through morphological and genetic parasite identification. Different subsequently applied anthelmintic compounds and protocols, including epsiprantel, did not confer the desired effects. Proglottid shedding only stopped after oral mebendazole administration of 86.2 mg kg−1 body weight for 5 consecutive days. Clinical signs resolved and the dog remained coproscopically negative during a follow-up period of 10 months after the last treatment. This case represents the first reported apparent praziquantel and epsiprantel resistance in D. caninum in Europe. Treatment was extremely challenging especially due to the limited availability of efficacious alternative compounds.


Subject(s)
Anthelmintics , Cestode Infections , Dog Diseases , Drug Resistance , Praziquantel , Animals , Praziquantel/therapeutic use , Praziquantel/pharmacology , Praziquantel/administration & dosage , Dogs , Dog Diseases/parasitology , Dog Diseases/drug therapy , Anthelmintics/pharmacology , Anthelmintics/therapeutic use , Cestode Infections/drug therapy , Cestode Infections/veterinary , Cestode Infections/parasitology , Switzerland , Cestoda/drug effects , Spain , Feces/parasitology , Male
20.
Vet Parasitol ; 328: 110182, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38603925

ABSTRACT

Anthelmintic performance against equine cyathostomins can be evaluated by two different non-terminal measures; the Fecal Egg Count Reduction Test (FECRT) and the Egg Reappearance Period (ERP). Most available FECRT and ERP data have been determined in populations of young horses, and very little information is available from mature and senior horses. Furthermore, it is unknown how commonly occurring equine endocrine disorders such as Insulin dysregulation (ID) and Pituitary pars intermedia dysfunction (PPID) may interfere with these measurements, but it has been suggested that horses with these conditions could be more susceptible to parasitic infections. A research population of senior horses and horses with or without PPID, ID, or both were enrolled in this study. All strongylid egg count positive horses were included in an ivermectin (200 µg/kg) efficacy study. These were distributed among the following groups: ID: six, PPID: three, PPID and ID: seven, and healthy controls: three. Strongylid fecal egg counts were determined on the day of ivermectin administration, at two weeks post deworming, and on weekly intervals until eight weeks post treatment. Determination of FECRT and ERP were carried out following World Association for the Advancement of Veterinary Parasitology guidelines. Results revealed high ivermectin efficacy with mean egg count reduction at 99.7% or above in all groups at two weeks post treatment. Egg reappearance was documented at six and seven weeks in the ID and PPID/ID groups, respectively, whereas the PPID and healthy control groups both had ERP at 8 weeks. Statistical analysis found no significant differences in egg count levels between groups during the study. The expected ERP for ivermectin is 8-10 weeks, meaning that two of the groups displayed shortened ERPs. However, due to the small group sizes, these data should be interpreted with caution. Nonetheless, results do indicate a need for further investigation of the possible influence of endocrine disorders on anthelmintic performance in horses.


Subject(s)
Feces , Horse Diseases , Ivermectin , Parasite Egg Count , Animals , Horses , Ivermectin/therapeutic use , Ivermectin/pharmacology , Horse Diseases/drug therapy , Horse Diseases/parasitology , Parasite Egg Count/veterinary , Feces/parasitology , Female , Endocrine System Diseases/veterinary , Endocrine System Diseases/drug therapy , Male , Anthelmintics/therapeutic use , Anthelmintics/pharmacology , Antiparasitic Agents/therapeutic use , Antiparasitic Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...